2. Gene
  3. Ager - advanced glycosylation end product-specific receptor Gene

Ager - advanced glycosylation end product-specific receptor Gene

  • 基因
  • 蛋白
  • 相关产品
  • 直系同源

种属: Rattus norvegicus

同用名: RAGE

基因 ID: 81722 | 基因类型: protein coding

关于 Ager

功能概要

Enables S100 protein binding activity and high mobility group box 1 binding activity. Involved in several processes, including positive regulation of apoptotic process; regulation of cell migration; and response to hexose. Located in several cellular components, including basal plasma membrane; cell surface; and neuronal cell body. Used to study several diseases, including diabetic retinopathy; impotence; renal fibrosis; thromboangiitis obliterans; and type 2 diabetes mellitus. Biomarker of several diseases, including bone disease (multiple); cardiovascular system disease (multiple); colorectal carcinoma; diabetic encephalopathy; and lung disease (multiple). Human ortholog(s) of this gene implicated in several diseases, including autoimmune disease (multiple); cardiovascular system disease (multiple); cystic fibrosis; kidney failure (multiple); and lupus nephritis. Orthologous to human AGER (advanced glycosylation end-product specific receptor). [provided by Alliance of Genome Resources, Apr 2022]

Ager 基因产物(1)

mRNA Protein Name
NM_053336.2 NP_445788.2 advanced glycosylation end product-specific receptor precursor
基因本体论
  • 分子功能
  • 生物过程
  • 细胞组分
分子功能 GO 注释 逻辑证据 参考文献 来源
enables S100 protein binding IPI
IPI: 通过物理相互作用推断
19910580 RGD
enables high mobility group box 1 binding IPI
IPI: 通过物理相互作用推断
22740883 RGD
enables protein binding IPI
IPI: 通过物理相互作用推断
7592757 RGD
生物过程 GO 注释 逻辑证据 参考文献 来源
involved in cell surface receptor signaling pathway via JAK-STAT IMP
IMP: 通过突变表型推断
11180401 RGD
involved in cellular response to fatty acid IEP
IEP: 通过表达模式推断
22217518 RGD
involved in cellular response to glucose stimulus IEP
IEP: 通过表达模式推断
20054520 RGD
involved in cellular response to hydrogen peroxide IEP
IEP: 通过表达模式推断
19885844 RGD
involved in cellular response to organic cyclic compound IEP
IEP: 通过表达模式推断
21807062 RGD
involved in cellular response to xenobiotic stimulus IEP
IEP: 通过表达模式推断
22467055 RGD
involved in glycoprotein metabolic process IEP
IEP: 通过表达模式推断
23348924 RGD
involved in lung development IEP
IEP: 通过表达模式推断
17343756 RGD
involved in negative regulation of cell adhesion IMP
IMP: 通过突变表型推断
22301267 RGD
involved in negative regulation of collagen biosynthetic process IMP
IMP: 通过突变表型推断
21872885 RGD
involved in negative regulation of endothelial cell migration IMP
IMP: 通过突变表型推断
22301267 RGD
involved in negative regulation of endothelial cell proliferation IMP
IMP: 通过突变表型推断
22301267 RGD
involved in negative regulation of osteoblast proliferation IEP
IEP: 通过表达模式推断
23529231 RGD
involved in negative regulation of protein phosphorylation IMP
IMP: 通过突变表型推断
21743278 RGD
involved in neuron projection development IGI
IGI: 通过遗传相互作用推断
7592757 RGD
involved in neuron projection development IMP
IMP: 通过突变表型推断
7592757 RGD
involved in positive regulation of apoptotic process IMP
IMP: 通过突变表型推断
19910580 RGD
involved in positive regulation of autophagy IMP
IMP: 通过突变表型推断
22293957 RGD
involved in positive regulation of cell migration IMP
IMP: 通过突变表型推断
19380826 RGD
involved in positive regulation of endothelial cell apoptotic process IMP
IMP: 通过突变表型推断
22301267 RGD
involved in positive regulation of epithelial to mesenchymal transition IMP
IMP: 通过突变表型推断
21743278 RGD
involved in positive regulation of fibroblast migration IMP
IMP: 通过突变表型推断
19959167 RGD
involved in positive regulation of fibroblast proliferation IMP
IMP: 通过突变表型推断
23053478 RGD
involved in positive regulation of gene expression IMP
IMP: 通过突变表型推断
21111711 RGD
involved in positive regulation of neuron apoptotic process IMP
IMP: 通过突变表型推断
22717618 RGD
involved in positive regulation of phagocytosis, engulfment IMP
IMP: 通过突变表型推断
23238794 RGD
involved in positive regulation of potassium ion transmembrane transporter activity IMP
IMP: 通过突变表型推断
23212096 RGD
involved in positive regulation of protein phosphorylation IMP
IMP: 通过突变表型推断
19885844 RGD
involved in positive regulation of reactive oxygen species metabolic process IMP
IMP: 通过突变表型推断
19885844 RGD
involved in positive regulation of smooth muscle cell migration IMP
IMP: 通过突变表型推断
23212096 RGD
involved in positive regulation of smooth muscle cell proliferation IMP
IMP: 通过突变表型推断
16368901 RGD
involved in positive regulation of type B pancreatic cell apoptotic process IMP
IMP: 通过突变表型推断
21111711 RGD
involved in response to activity IEP
IEP: 通过表达模式推断
23285277 RGD
involved in response to fructose IEP
IEP: 通过表达模式推断
21704028 RGD
involved in response to genistein IEP
IEP: 通过表达模式推断
21704028 RGD
involved in response to hyperoxia IEP
IEP: 通过表达模式推断
17343756 RGD
involved in response to methylglyoxal IEP
IEP: 通过表达模式推断
22425979 RGD
involved in response to selenite ion IEP
IEP: 通过表达模式推断
22476978 RGD
involved in response to vitamin A IEP
IEP: 通过表达模式推断
22274401 RGD
involved in transdifferentiation IEP
IEP: 通过表达模式推断
23403079 RGD
细胞组分 GO 注释 逻辑证据 参考文献 来源
located in axon IDA
IDA: 通过直接分析推断
7592757 RGD
located in basal plasma membrane IDA
IDA: 通过直接分析推断
9846897 RGD
located in cell surface IDA
IDA: 通过直接分析推断
17959934 RGD
located in extracellular space IDA
IDA: 通过直接分析推断
16456142 RGD
located in neuronal cell body IDA
IDA: 通过直接分析推断
7592757 RGD
EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断
蛋白主名 其他名称

advanced glycosylation end product-specific receptor

receptor for advanced glycosylation end products

相关产品

Approval
生物活性分子 (9)
目录号 产品名 作用方式
纯度 是否罕见病
HY-16561 Resveratrol 99.94% 是
HY-B0146 Verteporfin 99.58% 是
HY-147080 Avacincaptad pegol sodium Inhibitor 98.53% 否
HY-B0167A Sodium Salicylate 99.93% 是
HY-109561 Pegaptanib sodium Inhibitor 98.09% 否
HY-W012382 N-Acetyl-L-tyrosine 99.46% 否
HY-B0897 Bisoctrizole ≥98.0% 否
HY-14892 Gemigliptin Inhibitor / 否
HY-B0146R Verteporfin (Standard) / 否
抗体抑制剂 (2)
目录号 产品名 作用方式
纯度 是否罕见病
HY-108801 Aflibercept Inhibitor 97.90% 否
HY-P99116 Faricimab Inhibitor 97.97% 否
Clinical Phase
生物活性分子 (37)
目录号 产品名 作用方式
纯度 Phase
HY-I0626 Cytosine 99.99% Phase 4
HY-W013494 L-Carnosine 99.94% Phase 3
HY-106024B Alagebrium chloride Inhibitor 99.82% Phase 3
HY-P3252A Pegcetacoplan acetate Inhibitor 99.74% Phase 3
HY-B1745 Pyridoxylamine 99.91% Phase 3
HY-19720A Emixustat hydrochloride 99.29% Phase 3
HY-19720 Emixustat 98.00% Phase 3
HY-116098 Anecortave desacetate 98.36% Phase 3
HY-16467 Squalamine lactate Inhibitor 98.42% Phase 3
HY-153484A Bevasiranib sodium Inhibitor 97.68% Phase 3
HY-153484 Bevasiranib Inhibitor / Phase 3
HY-P0033A Argireline acetate Inhibitor / Phase 3
HY-112499 Menaquinone-7 ≥98.0% Phase 2
HY-128973 Pyropheophorbide-a ≥98.0% Phase 2
HY-P3204 POT-4 Inhibitor 99.64% Phase 2
HY-128850 N-Acetyl-D-mannosamine 99.58% Phase 2
HY-132806 Alogabat Agonist 99.93% Phase 2
HY-10186 TG 100801 Inhibitor 98.61% Phase 2
HY-136788 ALK4290 Inhibitor 99.79% Phase 2
HY-112499R Menaquinone-7 (Standard) 98.27% Phase 2
HY-14564 GTS-21 Agonist / Phase 2
HY-150177 Mannose 6 phosphate / Phase 2
HY-P1930 Risuteganib Inhibitor / Phase 2
HY-P3204A POT-4 TFA Inhibitor / Phase 2
HY-P5285 Lunasin Inhibitor 95.60% Phase 2
HY-W250163 NAD+ lithium / Phase 2
HY-10187 TG 100801 Hydrochloride Inhibitor / Phase 2
HY-N0088 Apocynin Inhibitor 99.94% Phase 1
HY-W050154 Kojic acid Inhibitor 99.99% Phase 1
HY-N0160 Kinetin 99.76% Phase 1
HY-136093A Lixumistat acetate Activator 99.88% Phase 1
HY-N1420 Rhamnose ≥98.0% Phase 1
HY-15114 S 17092 Inhibitor 99.78% Phase 1
HY-N1420A Rhamnose monohydrate 99.95% Phase 1
HY-136093 Lixumistat hydrochloride Activator 99.25% Phase 1
HY-16387 PF 00337210 Inhibitor / Phase 1
HY-19692 Itasetron Antagonist / Phase 1
抗体抑制剂 (4)
目录号 产品名 作用方式
纯度 Phase
HY-108801A Aflibercept (VEGF Trap) Inhibitor 97.66% Phase 4
HY-P99298 Lampalizumab Inhibitor 99.46% Phase 3
HY-P99576 Tarcocimab Inhibitor 98.35% Phase 3
HY-P99629 Galegenimab Inhibitor 99.91% Phase 2
Pre-clinical Phase
生物活性分子 (236)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-131042 NNMTi Inhibitor 99.70% 否
HY-W250118 Cephalin form bovine brain Activator ≥98.0% 否
HY-N0664 Aucubin Inhibitor 99.49% 否
HY-N1485 Cycloastragenol Activator ≥98.0% 否
HY-N0568 Madecassoside 99.58% 否
HY-120912 Gingerenone A Activator 99.95% 否
HY-N0033 Poliumoside Inhibitor 99.80% 否
HY-126255 SBI-797812 Activator 99.88% 否
HY-147313 TH10785 Activator 99.93% 否
HY-103157 PD146176 99.59% 否
HY-W015924 2-Hydroxyisobutyric acid ≥98.0% 否
HY-N0295 Protocatechualdehyde Inhibitor 99.98% 否
HY-16561R Resveratrol (Standard) 99.95% 否
HY-147059 Dieckol 99.38% 否
HY-P0033 Argireline Inhibitor 99.43% 否
HY-P2048A MOTS-c(human) acetate Activator 98.97% 否
HY-129460 XJB-5-131 Inhibitor 99.9% 否
HY-11068 SB 239063 Inhibitor 99.49% 否
HY-125623 MitoPerOx 98.14% 否
HY-402361 TERT activator-1 99.50% 否
HY-150069 UBX1325 99.16% 否
HY-129380 Fructosyl-lysine ≥97.0% 否
HY-W003607 3-O-Ethyl-L-ascorbic acid Inhibitor 99.94% 否
HY-P1928 Humanin Inhibitor 99.83% 否
HY-N0012 Glycitin Inhibitor 99.71% 否
HY-N5135 Liriopesides B 99.92% 否
HY-W001083 3-Hydroxyphenylacetic acid 99.03% 否
HY-110195 Smurf1-IN-A01 99.81% 否
HY-137817 BCH001 Inhibitor 98.83% 否
HY-P1149A Epitalon TFA Activator 99.62% 否
HY-159062 Goji Extract Activator / 否
HY-17442 Azathramycin Inhibitor 99.85% 否
HY-107811 Harmol 99.76% 否
HY-P1149 Epitalon Activator 99.50% 是
HY-N2292 Kinsenoside 99.91% 否
HY-W013573 S-Allyl-L-cysteine Inducer 98.64% 否
HY-N4170 Chebulic acid 99.26% 否
HY-76383 LR-90 Inhibitor 99.24% 否
HY-B1745A Pyridoxylamine dihydrochloride 99.93% 否
HY-108036A (S)-Pro-xylane ≥98.0% 否
HY-113303 FAPy-adenine 99.86% 否
HY-N6818 5,​7,​4'-​Trimethoxyflavone 99.65% 否
HY-133968 24-Methylenecholesterol 99.48% 否
HY-14892A Gemigliptin tartrate Inhibitor 98.17% 否
HY-106353 Smilagenin Agonist ≥98.0% 是
HY-N1517 Ganoderic acid C2 99.72% 否
HY-N2485 4'-Methoxyresveratrol 99.48% 否
HY-N4089 Quercetin 3-gentiobioside Inhibitor 99.92% 否
HY-N6588 3,4,5-Tricaffeoylquinic acid Inhibitor 98.71% 否
HY-129566 Withanolide B Activator ≥99.0% 否
HY-P5904 Caveolin-1 (82-101) amide (human, mouse, rat) Inhibitor 98.48% 否
HY-101528 IDRA 21 Modulator 99.39% 否
HY-108036 Pro-xylane (30% in water) ≥98.0% 否
HY-B1340 Carbadox Inhibitor ≥98.0% 否
HY-N0521 (-)-Gallocatechin 99.98% 否
HY-N7690 3,5,7,3′,4′-Pentamethoxyflavone Inhibitor 99.69% 否
HY-128387 2,3-Butanediol 99.96% 否
HY-128463 N-tert-Butyl-α-phenylnitrone Inhibitor 99.94% 否
HY-B1169 Timonacic ≥98.0% 否
HY-N2278 Kushenol A Inhibitor 99.98% 否
HY-W286743 Nε-(Carboxymethyl)-L-lysine 99.70% 否
HY-66015 Palmitoyl hexapeptide-12 97.38% 否
HY-P2048 MOTS-c (human) 99.90% 否
HY-W337672 H-Pro-Hyp-OH ≥99.0% 否
HY-43515 ESI1 99.76% 否
HY-129380A Fructosyl-lysine dihydrochloride ≥95.0% 否
HY-15289 Ciproxifan maleate Antagonist 99.68% 否
HY-154847 WM-662 Inhibitor 99.48% 否
HY-16561S Resveratrol-d4 99.36% 否
HY-W020086 2,3-Diaminophenazine 99.84% 否
HY-117924 AUTEN-67 Inducer 97.14% 否
HY-156781 Sirtuin-1 inhibitor 1 Inhibitor 98.09% 否
HY-110291 A-971432 Agonist ≥99.0% 否
HY-114653 SRPIN803 Inhibitor 99.17% 否
HY-N3026 Soyasaponin Ab 99.20% 否
HY-N3127 Orobol Inhibitor 99.28% 否
HY-N7628 Cassiaside C 99.90% 否
HY-P0064 Palmitoyl Tetrapeptide-3 Inhibitor 99.20% 否
HY-164159 α-Glucosylrutin Inhibitor 95.76% 否
HY-118060 Dipeptide 2 Inhibitor 97.89% 否
HY-163690 HTRA1-IN-1 Inhibitor / 否
HY-N2550A (+)-Coclaurine hydrochloride Control 99.09% 否
HY-P0102 Dipeptide diaminobutyroyl benzylamide diacetate Antagonist 99.63% 否
HY-P10409 SHLP2 99.18% 否
HY-139464 Q134R 99.55% 否
HY-147108 Mitochondria degrader-1 Inducer 95.10% 否
HY-169266 BRD-K56819078 Inhibitor 99.93% 否
HY-P2096 Hexapeptide-11 99.52% 否
HY-P3163 Hexapeptide-9 99.40% 否
HY-W585874 Nε-(Carboxyethyl)lysine Modulator 99.84% 否
HY-133859 M084 Inhibitor / 否
HY-P2663 Acetyl tetrapeptide-2 99.70% 否
HY-I0626S2 Cytosine-d2 99.69% 否
HY-W013494S L-Carnosine-d4 99.00% 否
HY-P1930A Risuteganib hydrochloride Inhibitor 98.54% 是
HY-11053 S 24795 Agonist 99.66% 否
HY-130221 (25S)-Δ7-Dafachronic acid 95.40% 否
HY-132126 SPHINX Inhibitor 99.87% 否
HY-153917 CRT0063465 Ligand 99.64% 否
HY-173463 Sirtuin modulator 8 Modulator 96.24% 否
HY-65008 N-Demethylricinine 99.94% 否
HY-N2947 Boeravinone B Inhibitor ≥97.0% 否
HY-N3757 (+)-Dihydrorobinetin ≥98.0% 否
HY-NP162 Recombinant Humanized Type XVII Collagen 95.00% 否
HY-P0095 Acetyl tetrapeptide-5 Inhibitor 98.97% 否
HY-P5251 Oligopeptide-68 98.89% 否
HY-W701069 Isomyosmine 97.38% 否
HY-124609 CAD031 99.39% 否
HY-126487A H-Arg-Lys-OH TFA 99.86% 否
HY-145486 1-Arachidonoyl-sn-glycerol 3-phosphate ammonium / 否
HY-15492 AG-13958 Inhibitor 99.71% 否
HY-156023 SIRT1 activator 2 Activator 99.28% 否
HY-157421 Nampt activator-4 Modulator / 否
HY-162866 CXM102 Activator / 否
HY-168336 E0924G Activator 99.17% 否
HY-N12486A (3S,8R,9R)-Isofalcarintriol / 否
HY-N2284 Sophoflavescenol Inhibitor 98.78% 否
HY-N7426 3-Deoxyglucosone 99.64% 否
HY-N9347 Stepharine Inhibitor ≥98.0% 否
HY-P0099 Pentapeptide-3 Antagonist 99.73% 否
HY-P5250 Palmitoyl tripeptide-5 Inhibitor / 否
HY-Q49697 Sirtuin modulator 3 Modulator 99.32% 否
HY-W012382S N-Acetyl-L-tyrosine-d3 98.43% 否
HY-14567 Ciproxifan Antagonist 99.26% 否
HY-RS17216 Ager Mouse Pre-designed siRNA Set A Pre-designed Set / 否
HY-158821 ISTH0036 / 否
HY-158821A ISTH0036 sodium / 否
HY-N6818R 5,?7,?4'-?Trimethoxyflavone (Standard) / 否
HY-107652 AF-DX 384 Antagonist 98.0% 否
HY-107811A Harmol hydrochloride / 否
HY-108036B Pro-xylane ≥98.0% 否
HY-113033A Pentosidine TFA / 否
HY-113127 L-Tryptophanamide / 否
HY-124223 AF-DX 384 methanesulfonate Antagonist / 否
HY-128135 MHY 553 Agonist / 否
HY-128387S 2,3-Butanediol-d6 / 否
HY-128387S1 2,3-Butanediol-d8 / 否
HY-128463S N-tert-Butyl-α-phenylnitrone-d14 / 否
HY-131528 Tenilsetam / 否
HY-133804 Arteanoflavone Inhibitor / 否
HY-133968S1 24-Methylenecholesterol-13C / 否
HY-136788A ALK4290 dihydrochloride Inhibitor / 否
HY-137557 Florzolotau / 否
HY-138830A (S,S)-TAK-418 Inhibitor / 否
HY-142778 Lp-PLA2-IN-10 / 否
HY-14567A Ciproxifan hydrochloride Antagonist / 否
HY-148322 Sirtuin modulator 5 Modulator / 否
HY-14892B Gemigliptin tartrate hydrate Inhibitor / 否
HY-151487 CypD-IN-3 Inhibitor / 否
HY-151488 CypD-IN-4 Inhibitor / 否
HY-151489 CypE-IN-1 Inhibitor / 否
HY-151546 MRS4596 Antagonist / 否
HY-151547 MRS4719 Antagonist / 否
HY-153183 Lp-PLA2-IN-12 Inhibitor / 否
HY-153560 Lp-PLA2-IN-14 Inhibitor / 否
HY-15492A AG-13958 (mono(hydrochloride)) Inhibitor / 否
HY-155138 GLS1 Inhibitor-7 Inhibitor / 否
HY-155988 Sirtuin modulator 6 Modulator / 否
HY-159007 BD-AcAc2 / 否
HY-159925 QKY-613 Activator / 否
HY-162269 Nampt activator-5 Activator / 否
HY-162515 8-OAc / 否
HY-162904 BPU17 / 否
HY-162968 MRTF-A-IN-1 Inhibitor / 否
HY-162969 MRTF-A-IN-2 Inhibitor / 否
HY-163403 VEGFR-2-IN-43 Inhibitor / 否
HY-16561G Resveratrol (GMP) / 否
HY-16561S1 Resveratrol-13C6 / 否
HY-167740 Glycerophosphoinositol (lysine) / 否
HY-169204 Mito-fisetin mF3 Inhibitor / 否
HY-169265 BRD-K20733377 Inhibitor / 否
HY-169846 CL5D / 否
HY-170794 ALT-007 Inhibitor / 否
HY-173337 HSP90α-IN-1 Inhibitor / 否
HY-174157 AR493 Activator / 否
HY-176127 JX10 Inhibitor / 否
HY-B0801AS Fexofenadine-d10 hydrochloride Inhibitor / 否
HY-B1340S Carbadox-d3 Inhibitor / 否
HY-E70022 D-Mannose isomerase (PsMaSeAF) / 否
HY-E70410 NAD Synthetase / 否
HY-I0626S Cytosine-13C2,15N3 / 否
HY-I0626S1 Cytosine-13C,15N2 / 否
HY-N0679S Retinyl acetate-d3 / 否
HY-N1097 Venoterpine / 否
HY-N1190 DL-Syringaresinol Inhibitor / 否
HY-N12653 Exserohilone Inhibitor / 否
HY-N13232 Grape Skin Extract / 否
HY-N13380 6′‐O‐Galloylsalidroside / 否
HY-N15152 Isoaesculioside D / 否
HY-N1517A (Rac)-Ganoderic acid C2 Inhibitor / 否
HY-N15225 12β-Hydroxyganoderenic acid B / 否
HY-N2550 (+)-Coclaurine / 否
HY-N3612 Communic acid Inhibitor / 否
HY-N6883 6-Methoxytricin Inhibitor / 否
HY-N8375 Sieboldin Inhibitor / 否
HY-P0104 Palmitoyl tripeptide-38 Inhibitor / 否
HY-P10140 JNK-IN-15, Cell-Permeable Inhibitor / 否
HY-P10141 JNK-IN-15, Cell-Permeable, Negative Control Inhibitor / 否
HY-P10611 [D-Ser14]-Humanin / 否
HY-P4308 Z-Pro-Pro-aldehyde-dimethyl acetal Inhibitor / 否
HY-P5233 Acetyltetrapeptide 11 Inhibitor / 否
HY-RS00444 AGER Human Pre-designed siRNA Set A Pre-designed Set / 否
HY-W001083S1 2-(3-Hydroxyphenyl-2,4,6-d3)acetic-2,2-d2 acid / 否
HY-W127725 Thymolphthalexon tetrasodium / 否
HY-W127738 6-O-Stearoyl-L-ascorbic acid / 否
HY-W128156 10-Hydroxystearic acid Agonist / 否
HY-Y0785 Glyoxal / 否
HY-107758 Y-29794 oxalate Inhibitor / 否
HY-113033 Pentosidine / 否
HY-123754 AGN-201904 Inhibitor / 否
HY-123904 UoS12258 Activator 99.86% 否
HY-138576 IDO1-IN-26 Inhibitor 98.22% 否
HY-142025 Daumone / 否
HY-145545 1-Stearoyl-2-Adrenoyl-sn-glycero-3-PE / 否
HY-149708 UCM-13207 Inhibitor 99.61% 否
HY-150361 Mouse Tert mRNA / 否
HY-154951 Oct4 inducer-2 Inducer / 否
HY-161088 Anti-aging agent 1 Inhibitor / 否
HY-163103 (S)-Isomyosmine / 否
HY-164066 Sodium Acetylated Hyaluronate / 否
HY-168957 RuDiOBn Inhibitor / 否
HY-169085 LRAT-IN-1 Inhibitor / 否
HY-174438 PSEC13 / 否
HY-175349 Tyrosinase-IN-43 Inhibitor / 否
HY-N12071 Lucidin-ω-Me ether / 否
HY-N12486 Isofalcarintriol / 否
HY-N13299 Glucoberteroin / 否
HY-N15147 Panax saponin C Activator / 否
HY-N8380 (-)-Latifolin / 否
HY-P3164 Acetyl tetrapeptide-9 / 否
HY-RS23668 Ager Rat Pre-designed siRNA Set A Pre-designed Set / 否
HY-W050154S Kojic acid-13C6 Inhibitor / 否
HY-W268155 3,4'-Dihydroxypropiophenone 95.35% 否
HY-W722107 Timonacic-d4 / 否
HY-W747597 Ganglioside GD1b Disodium Salt (Bovine Brain) / 否
HY-W997836 4-Amino-3-hydroxyphenylalanine / 否
抗体抑制剂 (10)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-P9951A Ranibizumab (anti-VEGF) Inhibitor ≥99.0% 否
HY-P990859 Anti-CD44 Antibody (Hermes-1) ≥95.0% 否
HY-P990328 Anti-AGER/RAGE Antibody (XT-M4) Inhibitor ≥99.0% 否
HY-P99905 Efdamrofusp alfa 99.89% 否
HY-P99402 Rinucumab Inhibitor 99.94% 否
HY-P991385 UBX2050 Inhibitor / 否
HY-P991415 ASKG-712 Antagonist / 否
HY-P991416 BAT5906 Inhibitor / 否
HY-P991418 MW02 Inhibitor / 否
HY-P991534 PF-04382923 Inhibitor / 否

直系同源

种属 基因名 来源 基因 ID
Homo sapiens Ager NCBI NCBI:177
Macaca fascicularis Ager NCBI NCBI:102121124
Mus musculus Ager NCBI NCBI:11596
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z